Search: Empty
HDBuzz: Unpacking Recent Gene Therapy Press
by admin
Voyager Therapeutics is shifting towards a new technology to deliver gene therapy and away from a planned HD clinical trial….
HD Advocate Testifies on HD Parity Act
by admin
Kala Booth, a Huntington’s disease positive individual and caregiver to her mother, will appear TODAY before the House Committee on Energy & Commerce subcommittee on neurodegenerative diseases. Kala…
Now Accepting Letters of Intent for 2022 HDSA Centers of Excellence!
by admin
HDSA Centers of Excellence provide comprehensive multidisciplinary clinical services to families affected by HD, including neurology, psychology, genetic counseling/testing, social…
Thank you for attending HDSA’s Virtual 36th Annual Convention!
by admin
Thank you to all who attended HDSA’s virtual 36th Annual Convention! If you missed us this time around, don’t stress—recorded sessions will be…
Webinar TODAY: Roche Community Update on GENERATION-HD1
by admin
Since the announcement in late March that dosing of tominersen in the GENERATION-HD1 trial had been halted, HD researchers and…
Volunteer Appreciation Week
by admin
This is Volunteer Appreciation Week and we would like to thank all the brave individuals who have volunteered their time…
More Disappointment in Wave PRECISION-HD Study Results
by admin
This Monday, March 29th, Wave Life Sciences shared a press release and community letter explaining that data from their PRECISION-HD1…
Disappointing news from Roche about GENERATION-HD1 study
by admin
We were saddened to learn on March 22nd via a press release and community statement from Roche that their Phase 3 study of tominersen, known as…
February 28th is Rare Disease Day
by admin
When you have a rare disease, you face two battles – one being the illness itself, and the other, living…
HDBuzz Explores a Novel Huntingtin-lowering Strategy
by admin
Huntingtin-lowering is an HD treatment strategy that usually involves targeting the HD gene itself, but some researchers are exploring roundabout ways to achieve…
Happy New Year From HDSA
by admin
Last year was a tough one for all of us, but HD research nevertheless made incredible progress, and we are…
HDBuzz: Clinical Research Updates from the HSG Conference
by admin
The Huntington Study Group hosted a virtual conference from October 29th – 31st, covering clinical trial updates, education, and training for HD…
HSG 2020: HD in Focus
by admin
The Huntington Study Group is a clinical research network focused exclusively on Huntington disease. Each year they host a conference that provides education…
Novartis Receives FDA Orphan Drug Designation to Study Potential HD Treatment
by admin
This week the pharmaceutical company Novartis announced that they had received special status from the FDA, known as Orphan Drug Designation,…
HDBuzz Covers Virtual EHDN Conference
by admin
The European Huntington’s Disease Network hosts a yearly Plenary meeting to discuss the latest in HD science and clinical trials,…
SIGNAL study of pepinemab does not meet key goals for HD patients
by admin
The SIGNAL study was carried out by a company called Vaccinex to test whether their drug, pepinemab, could combat brain inflammation and ease symptoms…
You Asked the Scientists!
by admin
The recording from the latest HDSA Research Webinar, Ask the Scientist Anything, is now available on HDSA’s YouTube channel. Dr….
Research Webinar: Ask the Scientist…Anything!
by admin
This coming Tuesday, September 8th, at 12 PM Eastern, Dr. Ed Wild and Dr. Jeff Carroll, creators of HDBuzz, as well as HDBuzz writers Dr….
HDBuzz on Somatic Instability
by admin
The cause of Huntington’s disease is an extra-long stretch of CAG repeats in the DNA, in a single gene called huntingtin. In…
HDBuzz: CRISPR Requires Caution
by admin
CRISPR is a gene editing technique that has been touted for its potential to treat HD someday in the future. However,…
